AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05340296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Youth Connect
Description: This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
Study NCT05642104 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant therapy
Description: all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
Study NCT05091788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Aime
Description: Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
Study NCT05412758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Stimulant Drink
Description: For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
Study NCT06314321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
Study NCT05585658 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin alpha
Description: To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
Study NCT05585658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin alpha
Description: To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
Study NCT05411809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug adjuvant therapy
Description: The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
Study NCT05683509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep collagen layer, xenograft and collagen membrane
Description: Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
Study NCT05683509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft and collagen membrane
Description: Alveolar ridge preservation is done using xenograft and collagen membrane only
Study NCT04668339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 single dose priming
Description: ARCT-021 higher dose (one dose) + placebo (one dose)
Study NCT04668339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 two lower dose priming
Description: ARCT-021 lower dose (two doses, Day 0 and Day 28)
Study NCT04668339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 two higher dose priming
Description: ARCT-021 higher dose (two doses, Day 0 and Day 28)
Study NCT04668339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (two doses), priming
Description: Placebo (two doses, Day 0 and Day 28)
Study NCT04668339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster
Study NCT04668339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo booster
Description: Placebo (single dose)
Study NCT06083233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventriculo-peritoneal shunt placement
Description: Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
Study NCT06083233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prechamber puncture
Description: Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
Study NCT06083233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #1
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
Study NCT06083233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #2
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
Study NCT06083233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #3
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
Study NCT06083233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #4 and #5
Description: Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
Study NCT06318403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
Study NCT06318403 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rotator Cuff Repair Surgery
Description: The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
Study NCT06318403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Repair Surgery
Description: The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
Study NCT06246916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
Study NCT06246916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: IV administration Q3W in combination with fianlimab
Study NCT06246916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: relatlimab+nivolumab
Description: IV administration every 4 weeks (Q4W)
Study NCT06137170 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Follow clinical administration.
Study NCT05926414 — intervention group
Intervention type: DRUG
Intervention: Enavogliflozin
Description: treated with Envlo tab. 0.3mg
Study NCT05926414 — intervention group
Intervention type: DRUG
Intervention: Enavogliflozin
Description: Envlomet SR Tablet 0.3/1,000mg
Study NCT04564898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days
Study NCT04564898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days
Study NCT04564898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days
Study NCT05704361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7121932 IV - SAD
Description: Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.
Study NCT05704361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7121932 SC - SAD
Description: Part 2: Participants will receive a single dose of RO7121932 administered as SC injection.
Study NCT05704361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7121932 - MAD
Description: Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.
Study NCT06286670 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Implant Fixation
Description: Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
Study NCT06286670 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual Implant Fixation
Description: Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
Study NCT04827563 — intervention group
Intervention type: DEVICE
Intervention: EndoPAT
Description: An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
Study NCT04827563 — intervention group
Intervention type: DEVICE
Intervention: Blood Pressure Cuff
Description: A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
Study NCT04827563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: A test used to conduct an ultrasound of participant's heart.
Study NCT04827563 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Assessment
Description: A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
Study NCT04827563 — intervention group
Intervention type: OTHER
Intervention: Blood Tests
Description: Routinely collected for all participants who begin carfilzomib treatment.
Study NCT04804644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Given PO
Study NCT04804644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: Ancillary studies
Study NCT04804644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessment
Description: Ancillary studies
Study NCT04804644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT04804644 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Brain Radiotherapy
Description: Undergo HA-WBRT
Study NCT06428903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 tablet
Description: ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
Study NCT05223816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG161
Description: Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections.
Study NCT06428903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 granules
Description: ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
Study NCT06428903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 180mg
Description: ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
Study NCT04998604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection subcutaneous
Study NCT04998604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: solution for injection subcutaneous
Study NCT04998604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution for injection subcutaneous
Study NCT06364371 — intervention group
Intervention type: OTHER
Intervention: Medical examination
Description: Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H\&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
Study NCT05361993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Aripiprazole
Description: Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
Study NCT05361993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback
Description: Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
Study NCT05951777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous HB-adMSCs
Description: Hope Biosciences autologous adipose-derived mesenchymal stem cells
Study NCT05951777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile Saline Solution 0.9%
Study NCT05671406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-controlled digital game
Description: The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors.
Study NCT05671406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensor only
Description: Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
Study NCT06101745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nizaracianine Triflutate
Description: Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.
Study NCT06101745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
Study NCT06085872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink Life Game
Description: REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
Study NCT06085872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested.
Study NCT06085872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoodWheel
Description: Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
Study NCT06155903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Spinal Anesthesia
Description: Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.